Evidence map›Paper›PMID 34149320›Full record

ReviewGastroHep2021

Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know?

Anna Licata, Maria Giovanna Minissale, Marco Distefano, Giuseppe Montalto

Open access · hybridAbstract readReview
In one paragraph

Review in GastroHep, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anna LicataInternal Medicine & Hepatology Section Department of Health Promotion Sciences, Maternal and Infant Care Internal Medicine and Medical Specialties PROMISE University of Palermo School of Medicine Palermo Italy.ORCID https://orcid.org/0000-0003-0383-6121
Maria Giovanna MinissaleInternal Medicine & Hepatology Section Department of Health Promotion Sciences, Maternal and Infant Care Internal Medicine and Medical Specialties PROMISE University of Palermo School of Medicine Palermo Italy.ORCID https://orcid.org/0000-0001-7850-555X
Marco DistefanoUOC Infectious Diseases ASP 8 Siracusa Italy.ORCID https://orcid.org/0000-0003-2616-4276
Giuseppe MontaltoInternal Medicine & Hepatology Section Department of Health Promotion Sciences, Maternal and Infant Care Internal Medicine and Medical Specialties PROMISE University of Palermo School of Medicine Palermo Italy.ORCID https://orcid.org/0000-0002-8731-8577
University of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19), which in males, especially in advanced age, can sometimes evolve into acute respiratory distress syndrome. In addition, mild to moderate alterations in liver function tests (LFTs) have been reported in the worst affected patients. Our review aims to analyse data on the incidence and prognostic value of LFT alterations, the underlying mechanisms and the management of pre-existing liver disease in COVID-19 affected patients.

methodsWe searched available literature through online PubMed database using terms as "SARS-CoV-2," "Liver damage," "Liver Function tests," "COVID-19," "pre-existing liver disease," "drug-induced liver injury."

resultsAvailable evidence suggest that there could be a relationship between SARS-CoV-2 infection and liver damage, although the underlying involved mechanism remains unclear. Cohort studies have shown that high ALT levels, low platelet counts and low albumin levels at admission and during hospitalisation are associated with a high mortality rate. Unfortunately, little is known about the impact of COVID-19 on pre-existing liver damage. While chronic viral infections or NAFLD are associated with an increased risk of COVID-19 progression, patients with cirrhosis may have increased susceptibility to SARS-CoV-2 infection due to their systemic immunocompromised status. DILI seems common among hospitalised patient with severe pneumonia.

conclusionMild to moderate liver impairment during Covid-19 is common, especially in patients with pre-existing liver disease. Further studies should be performed in order to understand how pre-existing liver conditions may influence and worsen progression of liver disease in COVID-19 patients.

Indexed as

COVID‐19Liver Function tests (LTFs)liver injurySARS‐CoV‐2

Identifiers

PMID34149320
PMCPMC8207035
OpenAlexW3157660030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.